Maxpro Capital Acquisition a Taiwan-based SPAC, priced its IPO of 9 million units at $10 each.
Units begin trading on the Nasdaq today under JMACU. Each consists of one share and one warrant. Once the securities begin separate trading, shares and warrants are expected to list under JMAC and JMACW.
Maxpro intends to focus on the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors.
The company is sponsored by an affiliate of Maxpro Ventures, a Taiwan based venture capital firm specialized in the healthcare industry.
EF Hutton is sole book-running manager for the offering. The underwriter has an option to purchase up to an additional 1.35 million units to cover any over-allotments. Read more.
